Evidence map›Paper›PMID 41410788›Full record

ArticleArchives of virology2025

Phenotypic effect of the mutations H78Y and L83V in the E6 protein of human papillomavirus.

N Di Domizio, A Debernardi, M Olivier, E Bôle-Richard, B Caël, S Gaillot, J-L Prétet, Q Lepiller

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

N Di DomizioUniversité Marie et Louis Pasteur, CNRS, Chrono-environnement, Besançon, F-25000, France.
A DebernardiUniversité Marie et Louis Pasteur, CNRS, Chrono-environnement, Besançon, F-25000, France.
M OlivierUniversité Marie et Louis Pasteur, CNRS, Chrono-environnement, Besançon, F-25000, France.
E Bôle-RichardFC Innov', F-25000, Bionovéo, Besançon, France.
B CaëlUniversité Marie et Louis Pasteur, INSERM, UMR1098, Besançon, F-25000, France.
S GaillotUniversité Marie et Louis Pasteur, CNRS, Chrono-environnement, Besançon, F-25000, France.
J-L PrétetUniversité Marie et Louis Pasteur, CNRS, Chrono-environnement, Besançon, F-25000, France.
Q LepillerUniversité Marie et Louis Pasteur, CNRS, Chrono-environnement, Besançon, F-25000, France. q1lepiller@chu-besancon.fr.ORCID http://orcid.org/0000-0003-2892-4216

Funding

Conseil Régional de Franche-Comté Conseil Régional de Franche-Comté
6 · The paper itself

Abstract

Human papillomavirus (HPV) 16 variants can differ in their oncogenic potential. Here, we investigated the effect of the amino acid substitutions H78Y and L83V in the E6 oncoprotein of HPV16 on early immune escape and p53 degradation in vitro. Although E6 inhibits the RIG-I-IRF-3-IFN-β pathway, this inhibition was not affected by the H78Y substitution. We found that the L83V mutation did not significantly affect p53 and p21 expression, cell migration and proliferation, or resistance to apoptosis. We therefore conclude that the H78Y and L83V substitutions in E6 had no phenotypic effect on early immune escape and p53 degradation, respectively, in our model.

Indexed as

Human papillomavirus 16Oncogene Proteins, ViralPapillomavirus InfectionsRepressor ProteinsAmino Acid SubstitutionApoptosisCell MovementCell ProliferationCyclin-Dependent Kinase Inhibitor p21Human Papillomavirus VirusesHumansImmune EvasionMutationPhenotypeTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p21E6 protein, Human papillomavirus type 16Oncogene Proteins, ViralRepressor ProteinsTumor Suppressor Protein p53CarcinogenesisE6 oncoproteinHPV16Immune escape

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.